Annovis to Attend the CTAD 2026 with Three Presentations
Annovis Bio will attend the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference November 16-19 in Boston, presenting three items on its lead drug candidate buntanetap. The presentations cover buntanetap's mechanism of action, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer's patients, and an AI-based approach to predicting blood-brain barrier permeability.
Key figures
- Conference
- CTAD 2026, November 16-19, Boston, MA
- Presentation count
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.